Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Future applications of copper-64-labeled daratumumab PET/CT in MM

Fluoro-deoxyglucose (FDG) positron-emission tomography/computed tomography (PET/CT) is one of the most widely used imaging techniques to detect multiple myeloma (MM), however intracellular FDG uptake can be seen in both malignant and non-malignant cells, resulting in limited sensitivity and specificity. Amrita Krishnan, MD, City of Hope Medical Center, Duarte, CA, outlines the various possible ways to make use of the Copper-64-labeled daratumumab PET/CT, that showed improved sensitivity when compared with FDG PET/CT (NCT03311828). Dr Krishnan explains this imaging technique could be used in patients with smoldering myeloma and possibly as a way of seeing if patients will respond to daratumumab therapy. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.